Loading organizations...
Genecast develops advanced liquid biopsy technology for comprehensive cancer management, covering early diagnosis, companion diagnostics, and minimal residual disease (MRD) testing. Their proprietary Allele-Discriminating Priming System (ADPS) and Digital ADPS platform achieve ultra-high 0.01% sensitivity, precisely detecting cancer gene mutations. These provide molecular insights for personalized treatment decisions, also developing specialized diagnostic enzymes.
Established November 2016, Genecast was co-founded by co-CEO Byung-Chul Lee, Ph.D. Dr. Lee, a biochemist and experienced biotech CTO, partnered with co-CEO Seung Chan Baek, who brings business leadership. Their insight targeted overcoming liquid biopsy limitations in sensitivity and multiplexing, striving for superior cancer diagnostic accuracy.
Genecast’s diagnostics support medical professionals for personalized cancer care in labs, hospitals, and research. Their vision is to make cancer a manageable disease, fostering healthier, longer lives. They achieve this through precise diagnostics, enabling earlier detection, informed therapies, and continuous patient monitoring.
Genecast has 2 tracked investments across 1 company. The latest tracked deal is $5.0M Other Equity in STAQ in May 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 19, 2016 | STAQ | $5.0M Other Equity | ZIV BEN Barouch | Core Capital, Kinetic Ventures, Revel Partners |
| May 1, 2016 | STAQ | $5.0M Series U | Pereg Ventures | Bessemer Venture Partners, Comcast Ventures, Erik Nordlander, Y Combinator, Core Capital, Kinetic Ventures, Revel Partners |
